Prenetics Finalizes $72 Million ACT Divestment, Bolsters Cash and Bitcoin Reserves to Accelerate IM8’s Path to $100 Million ARR

Posted on by
  • Strengthens financial position with more than $60 million in cash1, excluding Bitcoin holdings
  • IM8, co-founded by David Beckham, is projected to reach $100 million in Annual Recurring Revenue (ARR) in its first year, establishing it as one of the fastest-growing supplement brands in industry history
  • Bitcoin treasury increases to 255 BTC, with a strategy of purchasing 1 BTC daily since August; Net Asset Value (NAV) currently stands at $31.6 million, showing an unrealized gain of $3.86 million

CHARLOTTE, N.C., Oct. 07, 2025 — Prenetics Global Limited (NASDAQ: PRE), a prominent consumer health sciences firm, announced today the definitive conclusion of its sale of ACT Genomics Co., Ltd. (“ACT”) to Delta Electronics, Inc. (TWSE:2308). This transaction represents the final stage in Prenetics’ strategic withdrawal from the clinical diagnostics sector, allowing the company to dedicate its resources and focus to its rapidly expanding consumer health ventures.

The divestiture significantly enhances Prenetics’ financial stability. Based on its equity stake, Prenetics received $39.9 million in cash from the $72 million deal, with an additional approximately $6.3 million held in escrow, scheduled for release over the next 18 months, bringing Prenetics’ total proceeds to $46 million. This boosts Prenetics’ overall cash reserves to over $60 million1, not including its Bitcoin treasury, while maintaining a debt-free balance sheet. This robust financial base provides substantial capital to fuel the expansion of its primary consumer health brand, IM8.

This strategic pivot enables Prenetics to fully leverage the remarkable momentum of IM8, which is anticipated to achieve an annualized revenue run-rate (ARR) of $100 million within its initial 12 months post-launch. This growth trajectory positions IM8 as one of the most rapidly expanding supplement brands ever seen in the industry, showcasing strong market demand and execution.

Beyond its solid cash reserves, Prenetics also provided an update on its Bitcoin treasury strategy. The company now holds 255.4 BTC, with a current portfolio valuation of $31.6 million, representing a total investment of $27.8 million at an average cost of $108,972 per Bitcoin. This calculated allocation has generated an unrealized profit of $3.86 million, yielding a 13.9% return on the Bitcoin treasury investment, which commenced on June 16, 2025. Since August 1, 2025, Prenetics has adopted a systematic approach of acquiring 1 BTC daily, with all holdings securely held in custody at Kraken. For full transparency, all Bitcoin purchases and comprehensive analytics on the company’s BTC strategy are publicly accessible at .

“The completion of the ACT divestment marks a crucial transformation for Prenetics,” stated Danny Yeung, CEO and Co-Founder of Prenetics. “We have successfully streamlined our operations to concentrate entirely on our high-growth consumer health business, while simultaneously establishing a very robust balance sheet. With over $60 million in cash, zero debt, and our strategic Bitcoin treasury, we are exceptionally well-positioned to capitalize on IM8’s extraordinary growth. Our daily Bitcoin accumulation strategy reflects our long-term belief in digital assets as a treasury reserve, and we are eager to openly share this journey with our investors and stakeholders.”

About Prenetics
Prenetics (NASDAQ:PRE), a leading health sciences company, is committed to advancing consumer health. Our consumer initiatives include IM8, one of the world’s fastest-growing supplement brands, Europa, one of the largest sports distribution companies in the USA, and CircleDNA, a prominent direct-to-consumer DNA test. As the first consumer healthcare company to establish a Bitcoin treasury with an initial $20 million Bitcoin purchase and a board-approved comprehensive Bitcoin strategy, Prenetics is pioneering the convergence of healthcare innovation and digital asset adoption. To learn more, please visit www.prenetics.com and .

Investor Relations Contact:

PRE@mzgroup.us

Angela Cheung
Investor Relations / Corporate Finance

Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar statements. Prenetics may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (“SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Prenetics’ beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not to the following: the Company’s ability to execute its strategies, manage its growth, and achieve and maintain profitability; the Company’s ability to develop and commercialize its products and services; the Company’s ability to maintain and enhance its brand; the Company’s ability to compete effectively; the Company’s ability to continue to develop and maintain relationships with its partners and customers; the Company’s ability to protect its intellectual property; the Company’s ability to comply with applicable laws and regulations; and the Company’s ability to obtain additional financing. Further information regarding these and other risks is included in Prenetics’ filings with the SEC. All information provided in this press release is as of the date of this press release, and Prenetics does not undertake any duty to update such information, except as required under applicable law.

1. Total cash reserves assuming full settlement of transaction proceeds